J Crohn's and Colitis: Gut microbes predict the effectiveness of enteritis medication

January 28, 2021 /--- the prevalence of inflammatory bowel disease has increased significantly in Finland and worldwide.
these diseases cannot be completely cured.
if conventional drug therapy for anti-inflammatory drugs is not effective, the disease can be treated with infliximab monoantial, a biological TNF-α blocker administered intravenously.
infliximab monoantigen is an antibody that prevents the inflammatory factor TNF-α binding to inflammatory cells in the intestines.
is effective in reducing inflammation and improving patient conditions, while also providing good disease control.
(Photo: www.pixabay.com) Although infliximab monoantial therapy is usually effective, about 30-40% of patients do not respond to treatment or lose their response over time.
so far, there has been no reliable test for predicting therapeutic responses.
"A test to predict reactions will help to select drug therapies and avoid unnecessary drug use, which will reduce potential adverse reactions and save on drug costs in the health care system," said lead author and postdoctoral researcher Eija Nissilä.
project, researchers in the Department of Digestive Medicine at the University Hospital of Helsinki studied whether any predictors associated with infliximab monoantigen therapy could be found in the gut bacteriocytes.
study was published in Journal of Crohn's and Colitis.
study showed that the gut bacteriosty of patients with inflammatory bowel disease differed in several bacterial and fungal genus before treatment.
these differences are associated with infliximab mono-antitherapy responses.
changes in the intestinal bacteriobi during treatment also vary between patients who respond to treatment and those who do not.
non-responsive patients had fewer anti-inflammatory bacteria in the intestinal Bacillus difficile family, while more anti-inflammatory bacteria and fungi such as Candide.
bacteria found in the intestines foreshadowed a good response to infliximab monoantial therapy.
results, gut bacteria and fungi may be used as evaluation indicators when evaluating whether treatment is started.
predictive testing will make it possible to choose the right treatment, saving the cost of drug therapy in healthcare," said Nissilä, a researcher at the U.S. Department of Health.
" (Bioon.com) Source: Gutbiota if reveal drug therapies work in bowel diseases Original source: Rebecka Ventin-Holmberg et al, Created and Fungal Profiles as Markers of Infliximab Drug Response in Ingay Bowel Disease, Journal of Crohn's and Colitis (2020). DOI: 10.1093/ecco-jcc/jjaa252